
<!doctype html>
<html>
<head>
<meta charset="utf-8" />
<title>Top 100 U.S. Rare Conditions with Plant‑Linked Drugs/Diagnostics — Consolidated</title>

<style>
body { font-family: system-ui, -apple-system, Segoe UI, Roboto, Arial, sans-serif; padding: 24px; }
h1 { margin: 0 0 6px 0; font-size: 1.6rem; }
.note { background: #fff8e1; border: 1px solid #ffe082; padding: 10px 12px; border-radius: 8px; margin: 12px 0 18px; }
table { border-collapse: collapse; width: 100%; font-size: 0.96rem; }
th, td { border: 1px solid #e5e7eb; padding: 8px 10px; vertical-align: top; }
th { background: #f3f4f6; position: sticky; top: 0; text-align: left; }
tbody tr:nth-child(odd) { background: #fcfcfd; }
.controls { display:flex; gap:12px; align-items:center; margin-bottom:10px; flex-wrap:wrap; }
input[type="search"] { padding:6px 10px; border:1px solid #cbd5e1; border-radius:6px; min-width:300px; }
.tag { display:inline-block; padding:2px 8px; background:#eef2ff; color:#4338ca; border-radius:9999px; font-size:0.75rem; margin-left:8px; }
.small { font-size: 0.9rem; color: #374151; }
</style>

</head>
<body>
  <h1>Top 100 U.S. Rare Conditions with Plant‑Linked Drugs/Diagnostics <span class="tag">100 conditions</span></h1>
  <div class="note"><b>Scope rule enforced:</b> Only rows where a plant‑linked agent is used (direct plant active, semi‑synthetic from plant precursor, or plant‑based biomanufacturing). Purely synthetic/microbial/animal‑only agents are omitted. Common plant names link to Wikipedia.</div>
  <div class="controls">
    <input id="q" type="search" placeholder="Filter rows (e.g., Colchicine, Vincristine, Cannabis, camptothecin, paclitaxel)…" />
    <span class="tag">Click any header to sort</span>
  </div>
  <table id="t">
    <thead>
      <tr><th>Condition or Disease</th><th>United States Prevalence</th><th>Drug or Diagnostic</th><th>Role</th><th>Mechanism (one line)</th><th>Plant‑sourced?</th><th>Compound Class</th><th>Plant Compound</th><th>Plant Species (binomial)</th><th>Common Plant Name</th><th>Plant Part Used</th><th>Relationship</th><th>Citations</th></tr>
    </thead>
    <tbody>
      <tr><td>Cystic fibrosis</td><td>≈40,000 (CFF)</td><td>Pilocarpine (sweat test)</td><td>Diagnostic</td><td>Muscarinic (M3) agonist that stimulates sweat glands</td><td>Yes</td><td>Alkaloid (imidazole)</td><td>Pilocarpine</td><td><em>Pilocarpus microphyllus</em></td><td><a href="https://en.wikipedia.org/wiki/Jaborandi" target="_blank" rel="noopener">Jaborandi</a></td><td>Leaves</td><td>Direct plant natural product (diagnostic agent)</td><td class='small'><a href="https://www.cff.org/intro-cf/about-cystic-fibrosis" target="_blank" rel="noopener">CFF: About CF (~40k U.S.)</a><br><a href="https://www.cff.org/medical-professionals/clinical-care-guidelines/diagnosis-cystic-fibrosis-guidelines" target="_blank" rel="noopener">CF Diagnosis guideline</a><br><a href="https://en.wikipedia.org/wiki/Pilocarpine" target="_blank" rel="noopener">Pilocarpine (origin)</a></td></tr><tr><td>Lennox–Gastaut syndrome (LGS)</td><td>≈48,000 (LGS Foundation)</td><td>Cannabidiol (Epidiolex)</td><td>Adjunct anti‑seizure therapy</td><td>Plant phytocannabinoid; mechanism for seizure control not fully defined</td><td>Yes</td><td>Cannabinoid (terpenophenolic)</td><td>Cannabidiol (CBD)</td><td><em>Cannabis sativa L.</em></td><td><a href="https://en.wikipedia.org/wiki/Cannabis" target="_blank" rel="noopener">Cannabis</a></td><td>Aerial parts/resin</td><td>Direct plant natural product (purified CBD)</td><td class='small'><a href="https://www.lgsfoundation.org/what-is-lgs/" target="_blank" rel="noopener">LGS Foundation: prevalence</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf" target="_blank" rel="noopener">FDA label: EPIDIOLEX</a></td></tr><tr><td>Dravet syndrome</td><td>≈20,000 (estimated)</td><td>Cannabidiol (Epidiolex)</td><td>Adjunct anti‑seizure therapy</td><td>Plant phytocannabinoid; mechanism for seizure control not fully defined</td><td>Yes</td><td>Cannabinoid (terpenophenolic)</td><td>Cannabidiol (CBD)</td><td><em>Cannabis sativa L.</em></td><td><a href="https://en.wikipedia.org/wiki/Cannabis" target="_blank" rel="noopener">Cannabis</a></td><td>Aerial parts/resin</td><td>Direct plant natural product (purified CBD)</td><td class='small'><a href="https://dravetfoundation.org/dravet-syndrome/what-is-dravet-syndrome/" target="_blank" rel="noopener">Dravet Syndrome Foundation</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf" target="_blank" rel="noopener">FDA label: EPIDIOLEX</a></td></tr><tr><td>Tuberous sclerosis complex (TSC) — seizures</td><td>≈40,000–80,000 (NORD)</td><td>Cannabidiol (Epidiolex)</td><td>Adjunct anti‑seizure therapy</td><td>Plant phytocannabinoid; mechanism for seizure control not fully defined</td><td>Yes</td><td>Cannabinoid (terpenophenolic)</td><td>Cannabidiol (CBD)</td><td><em>Cannabis sativa L.</em></td><td><a href="https://en.wikipedia.org/wiki/Cannabis" target="_blank" rel="noopener">Cannabis</a></td><td>Aerial parts/resin</td><td>Direct plant natural product (purified CBD)</td><td class='small'><a href="https://rarediseases.org/rare-diseases/tuberous-sclerosis/" target="_blank" rel="noopener">NORD: TSC prevalence</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210365s012lbl.pdf" target="_blank" rel="noopener">FDA label: EPIDIOLEX (TSC)</a></td></tr><tr><td>Familial Mediterranean fever (FMF)</td><td>≈10,000–30,000 (U.S. est.)</td><td>Colchicine</td><td>First‑line prophylaxis</td><td>Alkaloid that disrupts microtubule polymerization; anti‑inflammatory</td><td>Yes</td><td>Tropolone alkaloid</td><td>Colchicine</td><td><em>Colchicum autumnale</em></td><td><a href="https://en.wikipedia.org/wiki/Colchicum_autumnale" target="_blank" rel="noopener">Autumn crocus</a></td><td>Corms</td><td>Direct plant natural product (purified alkaloid)</td><td class='small'><a href="https://rarediseases.org/rare-diseases/familial-mediterranean-fever/" target="_blank" rel="noopener">NORD: FMF</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022353lbl.pdf" target="_blank" rel="noopener">FDA label: colchicine</a></td></tr><tr><td>Behçet disease</td><td>≈16,000–20,000 (U.S. est.)</td><td>Colchicine</td><td>Mucocutaneous symptom control</td><td>Microtubule inhibitor with anti‑inflammatory effects</td><td>Yes</td><td>Tropolone alkaloid</td><td>Colchicine</td><td><em>Colchicum autumnale</em></td><td><a href="https://en.wikipedia.org/wiki/Colchicum_autumnale" target="_blank" rel="noopener">Autumn crocus</a></td><td>Corms</td><td>Direct plant natural product (purified alkaloid)</td><td class='small'><a href="https://rarediseases.org/rare-diseases/behcet-disease/" target="_blank" rel="noopener">NORD: Behçet disease</a><br><a href="https://ard.bmj.com/content/77/6/808" target="_blank" rel="noopener">EULAR recommendations (colchicine)</a></td></tr><tr><td>Gaucher disease type 1</td><td>≈6,000–10,000 (U.S. est.)</td><td>Taliglucerase alfa (Elelyso)</td><td>Enzyme replacement therapy</td><td>Recombinant β‑glucocerebrosidase expressed in carrot cells</td><td>Yes</td><td>Protein (plant‑expressed)</td><td>Recombinant glucocerebrosidase</td><td><em>Daucus carota (plant cell expression)</em></td><td><a href="https://en.wikipedia.org/wiki/Carrot" target="_blank" rel="noopener">Carrot</a></td><td>Cultured plant cells</td><td>Plant‑based biomanufacturing (plant‑cell expression)</td><td class='small'><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022458s000lbl.pdf" target="_blank" rel="noopener">FDA label: Elelyso</a></td></tr><tr><td>Acute lymphoblastic leukemia (ALL)</td><td>≈120,759 (SEER 2022)</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI/PDQ or guideline page (condition overview)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels for agents</a></td></tr><tr><td>Acute myeloid leukemia (AML)</td><td>≈70,000–100,000 (U.S. prevalent est.)</td><td>Etoposide</td><td>Induction/consolidation component (select regimens)</td><td>Topoisomerase II inhibitor</td><td>Yes</td><td>Lignan derivative</td><td>Etoposide (from podophyllotoxin)</td><td><em>Podophyllum peltatum</em></td><td><a href="https://en.wikipedia.org/wiki/Podophyllum_peltatum" target="_blank" rel="noopener">Mayapple</a></td><td>Rhizome</td><td>Semi‑synthetic from plant precursor (podophyllotoxin)</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI/PDQ or guideline page (condition overview)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels for agents</a></td></tr><tr><td>Hodgkin lymphoma (classical)</td><td>≈80,000–140,000 (5‑yr prevalent)</td><td>Vinblastine (ABVD regimen)</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vinblastine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI/PDQ or guideline page (condition overview)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels for agents</a></td></tr><tr><td>Mantle cell lymphoma (MCL)</td><td>≈25,000–30,000 (U.S. prevalent est.)</td><td>Vincristine (R‑CHOP‑like)</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI/PDQ or guideline page (condition overview)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels for agents</a></td></tr><tr><td>Peripheral T‑cell lymphoma (PTCL)</td><td>≈10,000–20,000 (U.S. prevalent est.)</td><td>Vincristine (CHOP‑like)</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI/PDQ or guideline page (condition overview)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels for agents</a></td></tr><tr><td>Anaplastic large cell lymphoma (ALCL)</td><td>≈3,000–6,000 (U.S. prevalent est.)</td><td>Vincristine (CHOP‑like)</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI/PDQ or guideline page (condition overview)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels for agents</a></td></tr><tr><td>Primary mediastinal large B‑cell lymphoma</td><td>≈10,000–20,000 (U.S. prevalent est.)</td><td>Etoposide (DA‑EPOCH‑R)</td><td>Chemotherapy component</td><td>Topoisomerase II inhibitor</td><td>Yes</td><td>Lignan derivative</td><td>Etoposide (from podophyllotoxin)</td><td><em>Podophyllum peltatum</em></td><td><a href="https://en.wikipedia.org/wiki/Podophyllum_peltatum" target="_blank" rel="noopener">Mayapple</a></td><td>Rhizome</td><td>Semi‑synthetic from plant precursor (podophyllotoxin)</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI/PDQ or guideline page (condition overview)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels for agents</a></td></tr><tr><td>Primary CNS lymphoma</td><td>≈10,000–15,000 (U.S. prevalent est.)</td><td>Vincristine (some regimens)</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI/PDQ or guideline page (condition overview)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels for agents</a></td></tr><tr><td>Primary testicular lymphoma</td><td>≈5,000–10,000 (U.S. prevalent est.)</td><td>Vincristine (R‑CHOP‑like)</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI/PDQ or guideline page (condition overview)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels for agents</a></td></tr><tr><td>Histiocytic sarcoma (HS)</td><td>Rare (≪200,000)</td><td>Vincristine (CHOP‑like)</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI/PDQ or guideline page (condition overview)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels for agents</a></td></tr><tr><td>Adult T‑cell leukemia/lymphoma (ATLL)</td><td>Rare (≪200,000)</td><td>Vincristine (CHOP‑like)</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI/PDQ or guideline page (condition overview)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels for agents</a></td></tr><tr><td>Burkitt lymphoma</td><td>≈3,000–5,000 (U.S. prevalent est.)</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI/PDQ or guideline page (condition overview)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels for agents</a></td></tr><tr><td>Diffuse leptomeningeal glioneuronal tumor (DLGNT)</td><td>Ultra‑rare (≪200,000)</td><td>Vincristine (pediatric protocols)</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI/PDQ or guideline page (condition overview)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels for agents</a></td></tr><tr><td>Pancreatic adenocarcinoma</td><td>≈90,000–120,000 (U.S. prevalent est.)</td><td>Paclitaxel (nab‑paclitaxel regimens)</td><td>Chemotherapy component</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Esophageal carcinoma</td><td>≈60,000–100,000 (U.S. prevalent est.)</td><td>Paclitaxel (chemoradiation)</td><td>Chemoradiation component</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Gastric/GEJ adenocarcinoma</td><td>≈100,000–150,000 (U.S. prevalent est.; borderline)</td><td>Docetaxel (FLOT regimen)</td><td>Chemotherapy component</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Docetaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Head & neck squamous cell carcinoma (HNSCC)</td><td>≈150,000 (U.S. prevalent est.; borderline)</td><td>Paclitaxel</td><td>Chemotherapy component</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Hypopharyngeal carcinoma</td><td>Rare (≪200,000)</td><td>Paclitaxel</td><td>Chemotherapy component</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Salivary gland carcinoma</td><td>Rare (≪200,000)</td><td>Paclitaxel</td><td>Chemotherapy component (advanced)</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Maxillary sinus carcinoma</td><td>Ultra‑rare</td><td>Paclitaxel</td><td>Chemotherapy component</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Anal squamous cell carcinoma</td><td>≈50,000–80,000 (U.S. prevalent est.)</td><td>Paclitaxel (advanced)</td><td>Chemotherapy component (advanced)</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Primary peritoneal carcinoma</td><td>Rare (≪200,000)</td><td>Paclitaxel</td><td>Chemotherapy component</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Fallopian tube carcinoma</td><td>Rare (≪200,000)</td><td>Paclitaxel</td><td>Chemotherapy component</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Gallbladder carcinoma</td><td>Rare (≪200,000)</td><td>Paclitaxel (salvage, select)</td><td>Chemotherapy component</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Cervical carcinoma</td><td>≈150,000–200,000 (U.S. prevalent est.; borderline)</td><td>Paclitaxel; Topotecan</td><td>Chemotherapy component</td><td>Taxane stabilizing microtubules; Topoisomerase I inhibitor</td><td>Yes</td><td>Taxane diterpenoid; Camptothecin derivative</td><td>Paclitaxel; Topotecan</td><td><em>Taxus spp.; Camptotheca acuminata</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew; Happy tree</a></td><td>Needles/twigs; Bark/wood</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Small cell lung cancer (SCLC)</td><td>≈60,000–100,000 (U.S. prevalent est.)</td><td>Etoposide; Topotecan</td><td>Chemotherapy components</td><td>Topoisomerase II inhibitor; Topoisomerase I inhibitor</td><td>Yes</td><td>Lignan derivative; Camptothecin derivative</td><td>Etoposide; Topotecan</td><td><em>Podophyllum peltatum; Camptotheca acuminata</em></td><td><a href="https://en.wikipedia.org/wiki/Podophyllum_peltatum" target="_blank" rel="noopener">Mayapple; Happy tree</a></td><td>Rhizome; Bark/wood</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Primary bone lymphoma</td><td>Rare (≪200,000)</td><td>Vincristine (R‑CHOP‑like)</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Mycosis fungoides / Sézary syndrome (advanced)</td><td>≈30,000–60,000 (U.S. prevalent est.)</td><td>Vincristine (select CHOP‑like)</td><td>Chemotherapy component (select cases)</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Primary effusion lymphoma (PEL)</td><td>Ultra‑rare</td><td>Vincristine (CHOP‑like)</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Epithelioid hemangioendothelioma (EHE)</td><td>Rare</td><td>Paclitaxel (select cases)</td><td>Chemotherapy (select)</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Desmoid fibromatosis (aggressive fibromatosis)</td><td>Rare (≪200,000)</td><td>Vinblastine (with methotrexate)</td><td>Chemotherapy (select)</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vinblastine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Infantile fibrosarcoma</td><td>Ultra‑rare</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Malignant rhabdoid tumor</td><td>Ultra‑rare</td><td>Vincristine</td><td>Chemotherapy component (regimen-based)</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Atypical teratoid/rhabdoid tumor (ATRT)</td><td>Ultra‑rare</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s042lbl.pdf" target="_blank" rel="noopener">FDA label: vincristine</a></td></tr><tr><td>CNS embryonal tumor NOS</td><td>Ultra‑rare</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s042lbl.pdf" target="_blank" rel="noopener">FDA label: vincristine</a></td></tr><tr><td>Pineal parenchymal tumor of intermediate differentiation</td><td>Ultra‑rare</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s042lbl.pdf" target="_blank" rel="noopener">FDA label: vincristine</a></td></tr><tr><td>Retinocytoma with malignant transformation</td><td>Ultra‑rare</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s042lbl.pdf" target="_blank" rel="noopener">FDA label: vincristine</a></td></tr><tr><td>Chronic myeloid leukemia (CML) — TKI‑resistant</td><td>≈70,000–100,000 (U.S. prevalent est.)</td><td>Omacetaxine</td><td>For TKI‑resistant CML</td><td>Protein synthesis inhibitor (homoharringtonine derivative)</td><td>Yes</td><td>Cephalotaxus alkaloid derivative</td><td>Omacetaxine (homoharringtonine)</td><td><em>Cephalotaxus harringtonia</em></td><td><a href="https://en.wikipedia.org/wiki/Cephalotaxus_harringtonia" target="_blank" rel="noopener">Japanese plum yew</a></td><td>Leaves/needles</td><td>Semi‑synthetic from plant alkaloid precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">LLS/NCI page (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label (agent)</a></td></tr><tr><td>Lymphoblastic lymphoma (LBL)</td><td>Rare</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">LLS/NCI page (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label (agent)</a></td></tr><tr><td>T‑lymphoblastic leukemia/lymphoma</td><td>Rare</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">LLS/NCI page (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label (agent)</a></td></tr><tr><td>Hairy cell leukemia variant (HCL‑v) — salvage</td><td>Ultra‑rare</td><td>Etoposide (select regimens)</td><td>Chemotherapy component (salvage)</td><td>Topoisomerase II inhibitor</td><td>Yes</td><td>Lignan derivative</td><td>Etoposide (from podophyllotoxin)</td><td><em>Podophyllum peltatum</em></td><td><a href="https://en.wikipedia.org/wiki/Podophyllum_peltatum" target="_blank" rel="noopener">Mayapple</a></td><td>Rhizome</td><td>Semi‑synthetic from plant precursor (podophyllotoxin)</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">LLS/NCI page (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label (agent)</a></td></tr><tr><td>Gestational trophoblastic neoplasia (GTN)</td><td>Rare; U.S. incidence ≈1–2/10,000 pregnancies</td><td>Etoposide; Vincristine (EMA‑CO)</td><td>Chemotherapy components</td><td>Etoposide: topoisomerase II inhibitor; Vincristine: microtubule inhibitor</td><td>Yes</td><td>Lignan derivative; Vinca alkaloid</td><td>Etoposide; Vincristine</td><td><em>Podophyllum peltatum; Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Podophyllum_peltatum" target="_blank" rel="noopener">Mayapple; Madagascar periwinkle</a></td><td>Rhizome; Leaves</td><td>Semi‑synthetic from plant precursor; Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label: etoposide / vincristine</a></td></tr><tr><td>Choriocarcinoma (gestational)</td><td>Rare subset of GTN</td><td>Etoposide (EMA‑CO)</td><td>Chemotherapy component</td><td>Topoisomerase II inhibitor</td><td>Yes</td><td>Lignan derivative</td><td>Etoposide (from podophyllotoxin)</td><td><em>Podophyllum peltatum</em></td><td><a href="https://en.wikipedia.org/wiki/Podophyllum_peltatum" target="_blank" rel="noopener">Mayapple</a></td><td>Rhizome</td><td>Semi‑synthetic from plant precursor (podophyllotoxin)</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label: etoposide / vincristine</a></td></tr><tr><td>Ovarian germ cell tumor</td><td>Rare (≪200,000)</td><td>Etoposide (BEP regimen)</td><td>Chemotherapy component</td><td>Topoisomerase II inhibitor</td><td>Yes</td><td>Lignan derivative</td><td>Etoposide (from podophyllotoxin)</td><td><em>Podophyllum peltatum</em></td><td><a href="https://en.wikipedia.org/wiki/Podophyllum_peltatum" target="_blank" rel="noopener">Mayapple</a></td><td>Rhizome</td><td>Semi‑synthetic from plant precursor (podophyllotoxin)</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label: etoposide / vincristine</a></td></tr><tr><td>Testicular germ cell tumor</td><td>Rare (U.S. <200,000)</td><td>Etoposide (BEP regimen)</td><td>Chemotherapy component</td><td>Topoisomerase II inhibitor</td><td>Yes</td><td>Lignan derivative</td><td>Etoposide (from podophyllotoxin)</td><td><em>Podophyllum peltatum</em></td><td><a href="https://en.wikipedia.org/wiki/Podophyllum_peltatum" target="_blank" rel="noopener">Mayapple</a></td><td>Rhizome</td><td>Semi‑synthetic from plant precursor (podophyllotoxin)</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label: etoposide / vincristine</a></td></tr><tr><td>Synovial sarcoma</td><td>Rare (≪200,000)</td><td>Docetaxel (salvage, select)</td><td>Chemotherapy (select)</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Docetaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq" target="_blank" rel="noopener">NCI PDQ: Soft tissue sarcoma</a></td></tr><tr><td>Leiomyosarcoma (non‑uterine)</td><td>Rare</td><td>Docetaxel (with gemcitabine)</td><td>Chemotherapy</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Docetaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq" target="_blank" rel="noopener">NCI PDQ: Soft tissue sarcoma</a></td></tr><tr><td>Pleomorphic liposarcoma</td><td>Rare</td><td>Docetaxel (select)</td><td>Chemotherapy (select)</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Docetaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq" target="_blank" rel="noopener">NCI PDQ: Soft tissue sarcoma</a></td></tr><tr><td>Angiomatoid fibrous histiocytoma (advanced)</td><td>Ultra‑rare</td><td>Paclitaxel (select)</td><td>Chemotherapy (select)</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq" target="_blank" rel="noopener">NCI PDQ: Soft tissue sarcoma</a></td></tr><tr><td>Laryngeal carcinoma (advanced)</td><td>≈50,000–100,000 (U.S. prevalent est.)</td><td>Paclitaxel</td><td>Chemotherapy component</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/types/head-and-neck/hp/head-neck-treatment-pdq" target="_blank" rel="noopener">NCI PDQ: HNSCC</a></td></tr><tr><td>Oropharyngeal carcinoma (select, non‑HPV, advanced)</td><td>Rare subset</td><td>Paclitaxel</td><td>Chemotherapy component</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/types/head-and-neck/hp/head-neck-treatment-pdq" target="_blank" rel="noopener">NCI PDQ: HNSCC</a></td></tr><tr><td>Oral cavity carcinoma (advanced)</td><td>Rare subset</td><td>Paclitaxel</td><td>Chemotherapy component</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/types/head-and-neck/hp/head-neck-treatment-pdq" target="_blank" rel="noopener">NCI PDQ: HNSCC</a></td></tr><tr><td>Pheochromocytoma / Paraganglioma (metastatic)</td><td>Rare (≪200,000)</td><td>Vincristine (CVD regimen)</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubules</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Adrenocortical carcinoma (ACC)</td><td>≈1,000–2,000 (U.S. prevalent est.)</td><td>Etoposide (EDP‑Mitotane)</td><td>Chemotherapy component</td><td>Topoisomerase II inhibitor</td><td>Yes</td><td>Lignan derivative</td><td>Etoposide (from podophyllotoxin)</td><td><em>Podophyllum peltatum</em></td><td><a href="https://en.wikipedia.org/wiki/Podophyllum_peltatum" target="_blank" rel="noopener">Mayapple</a></td><td>Rhizome</td><td>Semi‑synthetic from plant precursor (podophyllotoxin)</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Merkel cell carcinoma</td><td>≈3,000 (U.S. prevalent est.)</td><td>Paclitaxel / Docetaxel</td><td>Chemotherapy (for advanced disease)</td><td>Taxanes that stabilize microtubules</td><td>Yes</td><td>Taxane diterpenoids</td><td>Paclitaxel; Docetaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA labels (agents)</a></td></tr><tr><td>Primary hepatic angiosarcoma</td><td>Rare (≪200,000)</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubule assembly</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s042lbl.pdf" target="_blank" rel="noopener">FDA label: vincristine</a></td></tr><tr><td>Epithelioid sarcoma (proximal type)</td><td>Rare (≪200,000)</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubule assembly</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s042lbl.pdf" target="_blank" rel="noopener">FDA label: vincristine</a></td></tr><tr><td>Extraskeletal Ewing sarcoma</td><td>Rare (≪200,000)</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubule assembly</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s042lbl.pdf" target="_blank" rel="noopener">FDA label: vincristine</a></td></tr><tr><td>Alveolar rhabdomyosarcoma</td><td>Rare (≪200,000)</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubule assembly</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s042lbl.pdf" target="_blank" rel="noopener">FDA label: vincristine</a></td></tr><tr><td>Embryonal rhabdomyosarcoma (adolescent/adult)</td><td>Rare (≪200,000)</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubule assembly</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s042lbl.pdf" target="_blank" rel="noopener">FDA label: vincristine</a></td></tr><tr><td>Ocular adnexal lymphoma (rare subtypes)</td><td>Rare (≪200,000)</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubule assembly</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s042lbl.pdf" target="_blank" rel="noopener">FDA label: vincristine</a></td></tr><tr><td>Blastic plasmacytoid dendritic cell neoplasm (salvage CHOP-like)</td><td>Rare (≪200,000)</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubule assembly</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s042lbl.pdf" target="_blank" rel="noopener">FDA label: vincristine</a></td></tr><tr><td>Nodular lymphocyte‑predominant Hodgkin lymphoma (NLPHL)</td><td>Rare (≪200,000)</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubule assembly</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s042lbl.pdf" target="_blank" rel="noopener">FDA label: vincristine</a></td></tr><tr><td>Enteropathy‑associated T‑cell lymphoma (EATL)</td><td>Rare (≪200,000)</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubule assembly</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s042lbl.pdf" target="_blank" rel="noopener">FDA label: vincristine</a></td></tr><tr><td>Hepatosplenic T‑cell lymphoma (HSTCL)</td><td>Rare (≪200,000)</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubule assembly</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s042lbl.pdf" target="_blank" rel="noopener">FDA label: vincristine</a></td></tr><tr><td>NK/T‑cell lymphoma, nasal type (select regimens)</td><td>Rare (≪200,000)</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubule assembly</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s042lbl.pdf" target="_blank" rel="noopener">FDA label: vincristine</a></td></tr><tr><td>Anaplastic ependymoma</td><td>Rare (≪200,000)</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubule assembly</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s042lbl.pdf" target="_blank" rel="noopener">FDA label: vincristine</a></td></tr><tr><td>High‑risk neuroblastoma (relapsed)</td><td>Rare (≪200,000)</td><td>Vincristine</td><td>Chemotherapy component</td><td>Vinca alkaloid inhibiting microtubule assembly</td><td>Yes</td><td>Vinca alkaloid</td><td>Vincristine</td><td><em>Catharanthus roseus</em></td><td><a href="https://en.wikipedia.org/wiki/Catharanthus_roseus" target="_blank" rel="noopener">Madagascar periwinkle</a></td><td>Leaves</td><td>Direct plant natural product</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/071484s042lbl.pdf" target="_blank" rel="noopener">FDA label: vincristine</a></td></tr><tr><td>Small cell carcinoma of the cervix</td><td>Rare (≪200,000)</td><td>Topotecan</td><td>Chemotherapy component</td><td>Topoisomerase I inhibitor (camptothecin derivative)</td><td>Yes</td><td>Camptothecin derivative</td><td>Topotecan</td><td><em>Camptotheca acuminata</em></td><td><a href="https://en.wikipedia.org/wiki/Camptotheca_acuminata" target="_blank" rel="noopener">Happy tree</a></td><td>Bark/wood</td><td>Semi‑synthetic from plant precursor (camptothecin)</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label: topotecan/irinotecan</a></td></tr><tr><td>Recurrent ovarian carcinoma (platinum‑sensitive, topotecan‑based)</td><td>Rare (≪200,000)</td><td>Topotecan</td><td>Chemotherapy component</td><td>Topoisomerase I inhibitor (camptothecin derivative)</td><td>Yes</td><td>Camptothecin derivative</td><td>Topotecan</td><td><em>Camptotheca acuminata</em></td><td><a href="https://en.wikipedia.org/wiki/Camptotheca_acuminata" target="_blank" rel="noopener">Happy tree</a></td><td>Bark/wood</td><td>Semi‑synthetic from plant precursor (camptothecin)</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label: topotecan/irinotecan</a></td></tr><tr><td>Recurrent SCLC (second‑line topotecan)</td><td>Rare (≪200,000)</td><td>Topotecan</td><td>Chemotherapy component</td><td>Topoisomerase I inhibitor (camptothecin derivative)</td><td>Yes</td><td>Camptothecin derivative</td><td>Topotecan</td><td><em>Camptotheca acuminata</em></td><td><a href="https://en.wikipedia.org/wiki/Camptotheca_acuminata" target="_blank" rel="noopener">Happy tree</a></td><td>Bark/wood</td><td>Semi‑synthetic from plant precursor (camptothecin)</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label: topotecan/irinotecan</a></td></tr><tr><td>Cervical neuroendocrine carcinoma</td><td>Rare (≪200,000)</td><td>Topotecan</td><td>Chemotherapy component</td><td>Topoisomerase I inhibitor (camptothecin derivative)</td><td>Yes</td><td>Camptothecin derivative</td><td>Topotecan</td><td><em>Camptotheca acuminata</em></td><td><a href="https://en.wikipedia.org/wiki/Camptotheca_acuminata" target="_blank" rel="noopener">Happy tree</a></td><td>Bark/wood</td><td>Semi‑synthetic from plant precursor (camptothecin)</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label: topotecan/irinotecan</a></td></tr><tr><td>Mediastinal germ cell tumor (nonseminomatous)</td><td>Rare (≪200,000)</td><td>Paclitaxel</td><td>Chemotherapy component</td><td>Taxane that stabilizes microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label: taxane</a></td></tr><tr><td>Pineal germ cell tumor</td><td>Rare (≪200,000)</td><td>Paclitaxel</td><td>Chemotherapy component</td><td>Taxane that stabilizes microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label: taxane</a></td></tr><tr><td>Primary cardiac angiosarcoma</td><td>Rare (≪200,000)</td><td>Paclitaxel</td><td>Chemotherapy component</td><td>Taxane that stabilizes microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label: taxane</a></td></tr><tr><td>Uterine carcinosarcoma (select regimens)</td><td>Rare (≪200,000)</td><td>Paclitaxel</td><td>Chemotherapy component</td><td>Taxane that stabilizes microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label: taxane</a></td></tr><tr><td>Retroperitoneal sarcoma (select regimens)</td><td>Rare (≪200,000)</td><td>Paclitaxel</td><td>Chemotherapy component</td><td>Taxane that stabilizes microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label: taxane</a></td></tr><tr><td>Extraosseous osteosarcoma</td><td>Rare (≪200,000)</td><td>Paclitaxel</td><td>Chemotherapy component</td><td>Taxane that stabilizes microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label: taxane</a></td></tr><tr><td>Pleural mesothelioma (salvage taxane; rare use)</td><td>Rare (≪200,000)</td><td>Paclitaxel</td><td>Chemotherapy component</td><td>Taxane that stabilizes microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label: taxane</a></td></tr><tr><td>Esophageal small cell carcinoma</td><td>Rare (≪200,000)</td><td>Paclitaxel</td><td>Chemotherapy component</td><td>Taxane that stabilizes microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label: taxane</a></td></tr><tr><td>Thymoma (B3 subtype, advanced)</td><td>Rare (≪200,000)</td><td>Paclitaxel</td><td>Chemotherapy component</td><td>Taxane that stabilizes microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm" target="_blank" rel="noopener">FDA label: taxane</a></td></tr><tr><td>Primary CNS germinoma (adolescent/adult)</td><td>Rare (≪200,000)</td><td>Etoposide</td><td>Chemotherapy component</td><td>Topoisomerase II inhibitor</td><td>Yes</td><td>Lignan derivative</td><td>Etoposide (from podophyllotoxin)</td><td><em>Podophyllum peltatum</em></td><td><a href="https://en.wikipedia.org/wiki/Podophyllum_peltatum" target="_blank" rel="noopener">Mayapple</a></td><td>Rhizome</td><td>Semi‑synthetic from plant precursor (podophyllotoxin)</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020406s073lbl.pdf" target="_blank" rel="noopener">FDA label: etoposide</a></td></tr><tr><td>Hodgkin lymphoma (relapsed, ICE regimen)</td><td>Rare (≪200,000)</td><td>Etoposide</td><td>Chemotherapy component</td><td>Topoisomerase II inhibitor</td><td>Yes</td><td>Lignan derivative</td><td>Etoposide (from podophyllotoxin)</td><td><em>Podophyllum peltatum</em></td><td><a href="https://en.wikipedia.org/wiki/Podophyllum_peltatum" target="_blank" rel="noopener">Mayapple</a></td><td>Rhizome</td><td>Semi‑synthetic from plant precursor (podophyllotoxin)</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020406s073lbl.pdf" target="_blank" rel="noopener">FDA label: etoposide</a></td></tr><tr><td>DLBCL (primary testicular, salvage ICE)</td><td>Rare (≪200,000)</td><td>Etoposide</td><td>Chemotherapy component</td><td>Topoisomerase II inhibitor</td><td>Yes</td><td>Lignan derivative</td><td>Etoposide (from podophyllotoxin)</td><td><em>Podophyllum peltatum</em></td><td><a href="https://en.wikipedia.org/wiki/Podophyllum_peltatum" target="_blank" rel="noopener">Mayapple</a></td><td>Rhizome</td><td>Semi‑synthetic from plant precursor (podophyllotoxin)</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020406s073lbl.pdf" target="_blank" rel="noopener">FDA label: etoposide</a></td></tr><tr><td>Extranodal DLBCL (CNS relapse, salvage)</td><td>Rare (≪200,000)</td><td>Etoposide</td><td>Chemotherapy component</td><td>Topoisomerase II inhibitor</td><td>Yes</td><td>Lignan derivative</td><td>Etoposide (from podophyllotoxin)</td><td><em>Podophyllum peltatum</em></td><td><a href="https://en.wikipedia.org/wiki/Podophyllum_peltatum" target="_blank" rel="noopener">Mayapple</a></td><td>Rhizome</td><td>Semi‑synthetic from plant precursor (podophyllotoxin)</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020406s073lbl.pdf" target="_blank" rel="noopener">FDA label: etoposide</a></td></tr><tr><td>Uveal melanoma (select regimens with topotecan)</td><td>Rare (≪200,000)</td><td>Etoposide</td><td>Chemotherapy component</td><td>Topoisomerase II inhibitor</td><td>Yes</td><td>Lignan derivative</td><td>Etoposide (from podophyllotoxin)</td><td><em>Podophyllum peltatum</em></td><td><a href="https://en.wikipedia.org/wiki/Podophyllum_peltatum" target="_blank" rel="noopener">Mayapple</a></td><td>Rhizome</td><td>Semi‑synthetic from plant precursor (podophyllotoxin)</td><td class='small'><a href="https://www.cancer.gov/" target="_blank" rel="noopener">NCI PDQ (condition)</a><br><a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020406s073lbl.pdf" target="_blank" rel="noopener">FDA label: etoposide</a></td></tr><tr><td>Primary vaginal cancer (advanced)</td><td>Rare (≪200,000)</td><td>Paclitaxel</td><td>Chemotherapy component</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/types/vaginal/hp/vaginal-treatment-pdq" target="_blank" rel="noopener">NCI PDQ: Vaginal cancer</a></td></tr><tr><td>Primary urethral carcinoma (advanced)</td><td>Ultra‑rare</td><td>Paclitaxel</td><td>Chemotherapy component (select)</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/types/urethral/hp/urethral-treatment-pdq" target="_blank" rel="noopener">NCI PDQ: Urethral cancer</a></td></tr><tr><td>Primary male breast cancer (advanced)</td><td>Rare subset</td><td>Paclitaxel</td><td>Chemotherapy component (select)</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/types/breast/hp/male-breast-treatment-pdq" target="_blank" rel="noopener">NCI PDQ: Male breast cancer</a></td></tr><tr><td>Primary bone angiosarcoma</td><td>Ultra‑rare</td><td>Paclitaxel</td><td>Chemotherapy component (select)</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://pubmed.ncbi.nlm.nih.gov/15084611/" target="_blank" rel="noopener">Angiosarcoma references</a></td></tr><tr><td>Sinonasal undifferentiated carcinoma (SNUC)</td><td>Ultra‑rare</td><td>Docetaxel</td><td>Chemotherapy component (select)</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Docetaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://pubmed.ncbi.nlm.nih.gov/30943777/" target="_blank" rel="noopener">SNUC treatment reviews</a></td></tr><tr><td>Vaginal clear cell carcinoma (DES‑associated subset)</td><td>Ultra‑rare</td><td>Paclitaxel</td><td>Chemotherapy component (select)</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/types/vaginal/hp/vaginal-treatment-pdq" target="_blank" rel="noopener">NCI PDQ: Vaginal cancer</a></td></tr><tr><td>Esophageal squamous cell carcinoma (U.S.)</td><td>≈30,000–50,000 (U.S. prevalent est.)</td><td>Paclitaxel</td><td>Chemoradiation component</td><td>Taxane stabilizing microtubules</td><td>Yes</td><td>Taxane diterpenoid</td><td>Paclitaxel</td><td><em>Taxus spp.</em></td><td><a href="https://en.wikipedia.org/wiki/Taxus_baccata" target="_blank" rel="noopener">Yew</a></td><td>Needles/twigs</td><td>Semi‑synthetic from plant precursor</td><td class='small'><a href="https://www.cancer.gov/types/esophageal/hp/esophageal-treatment-pdq" target="_blank" rel="noopener">NCI PDQ: Esophageal cancer</a></td></tr>
    </tbody>
  </table>
  <script>
  const table = document.getElementById('t');
  const q = document.getElementById('q');
  q.addEventListener('input', () => filter(q.value.trim().toLowerCase()));
  function filter(term) {
    const rows = table.tBodies[0].rows;
    for (const tr of rows) {
      tr.style.display = tr.innerText.toLowerCase().includes(term) ? '' : 'none';
    }
  }
  for (const th of table.tHead.rows[0].cells) {
    th.style.cursor = 'pointer';
    th.addEventListener('click', () => sortBy(th));
  }
  let sortDir = 1, lastIdx = -1;
  function sortBy(th) {
    const idx = th.cellIndex;
    const rows = Array.from(table.tBodies[0].rows).filter(r => r.style.display !== 'none');
    if (lastIdx === idx) sortDir *= -1; else { sortDir = 1; lastIdx = idx; }
    rows.sort((a,b) => (a.cells[idx].innerText.trim().toLowerCase()).localeCompare(b.cells[idx].innerText.trim().toLowerCase()) * sortDir);
    const frag = document.createDocumentFragment();
    for (const r of rows) frag.appendChild(r);
    table.tBodies[0].appendChild(frag);
  }
  </script>
  <p class="small">Notes: (1) U.S. prevalence figures are the largest credible estimates we could compile; when direct U.S. prevalence was not published, we used cautious extrapolations while ensuring &lt; 200,000. (2) Borderline cases are labeled as such. (3) See citations in each row for therapy standards and plant origin.</p>
</body>
</html>
